LEIDEN, Netherlands, March 27, 2026
Pharming Group N.V. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending marketing authorization for Joenja® (leniolisib) for the treatment of Activated Phosphoinositide 3-Kinase Delta (APDS) syndrome, a rare and progressive primary immunodeficiency. The recommendation marks a critical regulatory milestone and brings the therapy closer to becoming the first approved treatment for APDS in the European Union, addressing a significant unmet medical need in rare disease management.
Regulatory Milestone Signals Imminent EU Approval
The positive CHMP opinion represents a major step toward European Commission approval, which is expected in Q2 2026 and, if granted, will enable commercialization across all EU member states, as well as Norway, Iceland, and Liechtenstein. This development underscores the growing importance of regulatory pathways in accelerating access to innovative therapies, particularly in rare diseases where treatment options are extremely limited.
Joenja is already approved in several regions including the United States and United Kingdom, reinforcing its validated clinical profile and regulatory acceptance globally. The EU recommendation further strengthens the drug’s commercial and clinical positioning and highlights Pharming’s commitment to expanding access to targeted therapies for rare genetic conditions.
Clinical Evidence Demonstrates Strong Efficacy and Safety
Advertisement
The CHMP’s recommendation is based on robust Phase II/III clinical trial data, including a randomized, placebo-controlled, triple-blind study involving patients aged 12 years and older diagnosed with APDS. The trial demonstrated statistically significant improvements in immune dysregulation and immunodeficiency markers, validating the drug’s ability to address the underlying cause of the disease rather than just managing symptoms.
Additional support was provided by long-term extension studies, where patients received treatment for a median duration of three years, confirming a favorable safety and tolerability profile. These findings are particularly important in rare diseases like APDS, where long-term management and sustained therapeutic benefit are critical for improving patient outcomes.
Joenja functions as an oral PI3Kδ inhibitor, targeting the dysregulated signaling pathway responsible for immune dysfunction in APDS patients. By directly addressing the genetic and molecular drivers of the disease, the therapy represents a precision medicine approach, setting a new benchmark in rare disease treatment.
Transforming Treatment Landscape for Rare Immunodeficiency
APDS is a rare, progressive, and often underdiagnosed condition, affecting approximately 1 to 2 individuals per million worldwide. Patients frequently experience severe infections, immune dysregulation, and delayed diagnosis, sometimes taking years before receiving appropriate treatment.
The introduction of Joenja in Europe could significantly transform the treatment paradigm, offering a targeted and disease-modifying therapy where previously only supportive care options were available. Experts emphasize that early intervention with such therapies could prevent long-term complications, including permanent organ damage and increased risk of malignancies.
This milestone also highlights the broader trend within biopharmaceutical innovation toward rare disease therapies, where advancements in genetics, immunology, and targeted drug design are enabling more effective and personalized treatments. Pharming’s continued investment in innovative biologics and small molecule therapies positions the company as a key player in addressing high unmet medical needs across global healthcare systems.
The CHMP positive opinion for Joenja (leniolisib) marks a significant advancement in the treatment of Activated PI3K Delta Syndrome, bringing hope to patients and healthcare providers across Europe. With strong clinical data, a well-defined mechanism of action, and regulatory momentum, Joenja is poised to become a first-in-class therapy in the EU, reinforcing the critical role of biopharma innovation in rare disease management.
Source: Pharming Group press release
